NEW YORK (GenomeWeb News) – Caliper Life Sciences today reported that its second-quarter revenues fell around 6 percent, but were up 8 percent on an organic basis, as the firm trimmed its net loss. It also beat analysts' consensus estimate for both revenues and net loss.

The Hopkinton, Mass.-based firm's stock was up 11 percent to $1.95 in early Thursday trade on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.